Media coverage about Medpace (NASDAQ:MEDP) has trended somewhat negative this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a daily sentiment score of -0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9951225201493 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of equities research analysts have recently issued reports on MEDP shares. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a research report on Tuesday, July 3rd. William Blair raised shares of Medpace from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 31st. BidaskClub cut shares of Medpace from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Credit Suisse Group boosted their target price on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a research report on Tuesday, July 31st. Finally, TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. Six analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $43.83.
MEDP opened at $57.83 on Friday. Medpace has a twelve month low of $30.62 and a twelve month high of $63.97. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.68 and a quick ratio of 0.68. The stock has a market cap of $2.08 billion, a P/E ratio of 38.05, a PEG ratio of 1.50 and a beta of 1.00.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Tuesday, July 31st. The company reported $0.61 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.19. Medpace had a net margin of 10.44% and a return on equity of 14.22%. The business had revenue of $117.80 million during the quarter, compared to analysts’ expectations of $104.97 million. During the same quarter in the prior year, the business posted $0.38 earnings per share. Medpace’s revenue was up 24.5% compared to the same quarter last year. analysts anticipate that Medpace will post 2.44 EPS for the current fiscal year.
In related news, major shareholder Medpace Limited Partnership sold 5,224,997 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $54.75, for a total transaction of $286,068,585.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO August J. Troendle sold 731,460 shares of the company’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $59.26, for a total transaction of $43,346,319.60. Following the sale, the chief executive officer now directly owns 849,621 shares of the company’s stock, valued at approximately $50,348,540.46. The disclosure for this sale can be found here. Insiders have sold 14,510,659 shares of company stock valued at $758,531,950 in the last ninety days. 29.50% of the stock is currently owned by company insiders.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Recommended Story: Stop Order
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.